Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Quanz M, Bender E, Kopitz C, Grünewald S, Schlicker A, Schwede W, Eheim A, Toschi L, Neuhaus R, Richter C, Toedling J, Merz C, Lesche R, Kamburov A, Siebeneicher H, Bauser M, Hägebarth A.

Mol Cancer Ther. 2018 Nov;17(11):2285-2296. doi: 10.1158/1535-7163.MCT-17-1253. Epub 2018 Aug 16.

PMID:
30115664
2.

Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis.

Pamfil C, Makowska Z, De Groof A, Tilman G, Babaei S, Galant C, Montigny P, Demoulin N, Jadoul M, Aydin S, Lesche R, McDonald F, Houssiau FA, Lauwerys BR.

Ann Rheum Dis. 2018 Dec;77(12):1782-1789. doi: 10.1136/annrheumdis-2018-213485. Epub 2018 Jul 31.

3.

Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction.

Wilck N, Markó L, Balogh A, Kräker K, Herse F, Bartolomaeus H, Szijártó IA, Gollasch M, Reichhart N, Strauss O, Heuser A, Brockschnieder D, Kretschmer A, Lesche R, Sohler F, Stasch JP, Sandner P, Luft FC, Müller DN, Dechend R, Haase N.

JCI Insight. 2018 Feb 22;3(4). pii: 96006. doi: 10.1172/jci.insight.96006. [Epub ahead of print]

4.

Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.

Gelato KA, Schöckel L, Klingbeil O, Rückert T, Lesche R, Toedling J, Kalfon E, Héroult M, Lejeune P, Mönning U, Fernández-Montalván AE, Bäurle S, Siegel S, Haendler B.

Oncogene. 2018 Jan 25;37(4):512-521. doi: 10.1038/onc.2017.325. Epub 2017 Oct 9.

5.

Functional inhibition of acid sphingomyelinase by Fluphenazine triggers hypoxia-specific tumor cell death.

Klutzny S, Lesche R, Keck M, Kaulfuss S, Schlicker A, Christian S, Sperl C, Neuhaus R, Mowat J, Steckel M, Riefke B, Prechtl S, Parczyk K, Steigemann P.

Cell Death Dis. 2017 Mar 30;8(3):e2709. doi: 10.1038/cddis.2017.130.

6.

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.

Klingbeil O, Lesche R, Gelato KA, Haendler B, Lejeune P.

Cell Death Dis. 2016 Sep 8;7(9):e2365. doi: 10.1038/cddis.2016.271.

7.

Contour identical implants to bridge mandibular continuity defects--individually generated by LaserCUSING®--A feasibility study in animal cadavers.

Reitemeier B, Schöne C, Lesche R, Lauer G, Schulz MC, Markwardt J.

Head Face Med. 2016 Apr 11;12:17. doi: 10.1186/s13005-016-0114-0.

8.

EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.

Hernando H, Gelato KA, Lesche R, Beckmann G, Koehr S, Otto S, Steigemann P, Stresemann C.

Mol Cancer Ther. 2016 Feb;15(2):287-98. doi: 10.1158/1535-7163.MCT-15-0486. Epub 2015 Nov 20.

9.

One vs. two piece customized implants to reconstruct mandibular continuity defects: a preliminary study in pig cadavers.

Markwardt J, Weber T, Modler N, Sembdner P, Lesche R, Schulz MC, Reitemeier B.

J Craniomaxillofac Surg. 2014 Sep;42(6):790-5. doi: 10.1016/j.jcms.2013.11.013. Epub 2013 Nov 16.

PMID:
24342731
10.

Experimental findings on customized mandibular implants in Göttingen minipigs - a pilot study.

Markwardt J, Sembdner P, Lesche R, Jung R, Spekl K, Mai R, Schulz MC, Reitemeier B.

Int J Surg. 2014;12(5):60-6. doi: 10.1016/j.ijsu.2013.10.011. Epub 2013 Nov 2.

11.

Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer.

Lesche R, Kettschau G, Gromov AV, Böhnke N, Borkowski S, Mönning U, Hegele-Hartung C, Döhr O, Dinkelborg LM, Graham K.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):89-101. doi: 10.1007/s00259-013-2527-3. Epub 2013 Aug 17.

PMID:
23955632
12.

Experimental study on the behavior of primary human osteoblasts on laser-cused pure titanium surfaces.

Markwardt J, Friedrichs J, Werner C, Davids A, Weise H, Lesche R, Weber A, Range U, Meißner H, Lauer G, Reitemeier B.

J Biomed Mater Res A. 2014 May;102(5):1422-30. doi: 10.1002/jbm.a.34824. Epub 2013 Jun 20.

PMID:
23775939
13.

Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer.

Graham K, Lesche R, Gromov AV, Böhnke N, Schäfer M, Hassfeld J, Dinkelborg L, Kettschau G.

J Med Chem. 2012 Nov 26;55(22):9510-20. doi: 10.1021/jm300710j. Epub 2012 Oct 24.

PMID:
23025786
14.

Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients.

Göbel G, Auer D, Gaugg I, Schneitter A, Lesche R, Müller-Holzner E, Marth C, Daxenbichler G.

Breast Cancer Res Treat. 2011 Nov;130(1):109-17. doi: 10.1007/s10549-010-1335-8. Epub 2011 Jan 8.

PMID:
21221769
15.

CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.

Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JW.

BMC Cancer. 2010 Jun 1;10:247. doi: 10.1186/1471-2407-10-247.

16.

Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation.

Schatz P, Dietrich D, Koenig T, Burger M, Lukas A, Fuhrmann I, Kristiansen G, Stoehr R, Schuster M, Lesche R, Weiss G, Corman J, Hartmann A.

J Mol Diagn. 2010 May;12(3):345-53. doi: 10.2353/jmoldx.2010.090088. Epub 2010 Mar 19.

17.

Quantitative DNA methylation profiling on a high-density oligonucleotide microarray.

Fassbender A, Lewin J, König T, Rujan T, Pelet C, Lesche R, Distler J, Schuster M.

Methods Mol Biol. 2010;576:155-70. doi: 10.1007/978-1-59745-545-9_9.

PMID:
19882262
18.

DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy.

Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, Haefliger C, Lesche R, Hartmann A, Corman J, Wheeler T.

J Urol. 2009 Apr;181(4):1678-85. doi: 10.1016/j.juro.2008.11.120. Epub 2009 Feb 23.

PMID:
19233404
19.

Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues.

Dietrich D, Lesche R, Tetzner R, Krispin M, Dietrich J, Haedicke W, Schuster M, Kristiansen G.

J Histochem Cytochem. 2009 May;57(5):477-89. doi: 10.1369/jhc.2009.953026. Epub 2009 Jan 19.

20.

DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.

Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A, Niemann S, Foekens JA, Lesche R, Martens JW.

Clin Cancer Res. 2009 Jan 1;15(1):315-23. doi: 10.1158/1078-0432.CCR-08-0166.

21.

Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.

Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grützmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Müller V, Milde-Langosch K, Nährig J, Foekens J, Maier S, Schmitt M, Lesche R.

J Clin Oncol. 2008 Nov 1;26(31):5036-42. doi: 10.1200/JCO.2007.14.1697. Epub 2008 Aug 18.

PMID:
18711169
22.
23.

DNA methylation biomarkers for blood-based colorectal cancer screening.

Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, Song X, Lesche R, Liebenberg V, Ebert M, Molnar B, Grützmann R, Pilarsky C, Sledziewski A.

Clin Chem. 2008 Feb;54(2):414-23. Epub 2007 Dec 18.

24.

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.

Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, Magdolen V, Portengen H, Look MP, Klijn JG, Lesche R, Schmitt M, Maier S, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2008 Oct;111(3):429-37. Epub 2007 Oct 28.

PMID:
17965955
25.

The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study.

Golouh R, Cufer T, Sadikov A, Nussdorfer P, Usher PA, Brünner N, Schmitt M, Lesche R, Maier S, Timmermans M, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2008 Jul;110(2):317-26. Epub 2007 Sep 13.

PMID:
17874182
26.

[DNA methylation: potential for diagnosis, prognosis and therapy--prediction in oncology].

Haedicke W, Lesche R.

Verh Dtsch Ges Pathol. 2006;90:39-45. German.

PMID:
17867578
27.

DNA methylation markers: a versatile diagnostic tool for routine clinical use.

Lesche R, Eckhardt F.

Curr Opin Mol Ther. 2007 Jun;9(3):222-30. Review.

PMID:
17608020
28.

DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, Schittulli F, Kates R, Lesche R, Schwope I, Kluth A, Marx A, Martens JW, Foekens JA, Schmitt M, Harbeck N; European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.

Eur J Cancer. 2007 Jul;43(11):1679-86. Epub 2007 Jun 29.

PMID:
17601725
29.

DNA methylation profiling of transcription factor genes in normal lymphocyte development and lymphomas.

Ivascu C, Wasserkort R, Lesche R, Dong J, Stein H, Thiel A, Eckhardt F.

Int J Biochem Cell Biol. 2007;39(7-8):1523-38. Epub 2007 Feb 14.

PMID:
17433759
30.

Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease.

Model F, Osborn N, Ahlquist D, Gruetzmann R, Molnar B, Sipos F, Galamb O, Pilarsky C, Saeger HD, Tulassay Z, Hale K, Mooney S, Lograsso J, Adorjan P, Lesche R, Dessauer A, Kleiber J, Porstmann B, Sledziewski A, Lofton-Day C.

Mol Cancer Res. 2007 Feb;5(2):153-63.

31.

Genetic background controls tumor development in PTEN-deficient mice.

Freeman D, Lesche R, Kertesz N, Wang S, Li G, Gao J, Groszer M, Martinez-Diaz H, Rozengurt N, Thomas G, Liu X, Wu H.

Cancer Res. 2006 Jul 1;66(13):6492-6.

32.

Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia.

Osborn NK, Zou H, Molina JR, Lesche R, Lewin J, Lofton-Day C, Klatt KK, Harrington JJ, Burgart LJ, Ahlquist DA.

Clin Gastroenterol Hepatol. 2006 Feb;4(2):212-8.

PMID:
16469682
33.

DNA methylation markers - an opportunity to further individualize therapy in breast cancer?

Maier S, Lesche R, Nimmrich I, Eckhardt F, Dahlstroem C, Plum A.

Per Med. 2005 Nov;2(4):339-347. doi: 10.2217/17410541.2.4.339.

PMID:
29788573
34.

Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected].

Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, Sherwin R, Devaskar S, Lesche R, Magnuson MA, Wu H.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):2082-7. Epub 2004 Feb 9. Erratum in: Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5180.

36.

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.

Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, Liu X, Wu H.

Cancer Cell. 2003 Feb;3(2):117-30.

37.

Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland.

Li G, Robinson GW, Lesche R, Martinez-Diaz H, Jiang Z, Rozengurt N, Wagner KU, Wu DC, Lane TF, Liu X, Hennighausen L, Wu H.

Development. 2002 Sep;129(17):4159-70.

38.

Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis.

Stiles B, Gilman V, Khanzenzon N, Lesche R, Li A, Qiao R, Liu X, Wu H.

Mol Cell Biol. 2002 Jun;22(11):3842-51.

39.

Tumour class prediction and discovery by microarray-based DNA methylation analysis.

Adorján P, Distler J, Lipscher E, Model F, Müller J, Pelet C, Braun A, Florl AR, Gütig D, Grabs G, Howe A, Kursar M, Lesche R, Leu E, Lewin A, Maier S, Müller V, Otto T, Scholz C, Schulz WA, Seifert HH, Schwope I, Ziebarth H, Berlin K, Piepenbrock C, Olek A.

Nucleic Acids Res. 2002 Mar 1;30(5):e21.

40.

Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene.

Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H.

Genesis. 2002 Feb;32(2):148-9. No abstract available.

PMID:
11857804
41.

Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo.

Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp A, Zack JA, Kornblum HI, Liu X, Wu H.

Science. 2001 Dec 7;294(5549):2186-9. Epub 2001 Nov 1.

42.

Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases.

Liliental J, Moon SY, Lesche R, Mamillapalli R, Li D, Zheng Y, Sun H, Wu H.

Curr Biol. 2000 Apr 6;10(7):401-4.

43.

A sensitized genetic system for the analysis of murine B lymphocyte signal transduction pathways dependent on Bruton's tyrosine kinase.

Satterthwaite AB, Willis F, Kanchanastit P, Fruman D, Cantley LC, Helgason CD, Humphries RK, Lowell CA, Simon M, Leitges M, Tarakhovsky A, Tedder TF, Lesche R, Wu H, Witte ON.

Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6687-92.

44.

PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway.

Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X, Wu H.

Proc Natl Acad Sci U S A. 1999 May 25;96(11):6199-204.

45.

The dominant mouse mutations fused toes (Ft) and oligosyndactylism (Os) are not allelic.

Lesche R, Rüther U.

Mamm Genome. 1998 Jul;9(7):588-9. No abstract available.

PMID:
9657858
46.

Close linkage of p130 and Ft1 is conserved among mammals.

Lesche R, Rüther U.

Mamm Genome. 1998 Mar;9(3):253-5. No abstract available.

PMID:
9501314
47.

Ft1, a novel gene related to ubiquitin-conjugating enzymes, is deleted in the Fused toes mouse mutation.

Lesche R, Peetz A, van der Hoeven F, Rüther U.

Mamm Genome. 1997 Dec;8(12):879-83.

PMID:
9383278
48.

[Fluid balance in calves. 2. Body fluid compartments depending on the age of the animal and changes caused by diarrhea].

Hartmann H, Finsterbusch L, Lesche R.

Arch Exp Veterinarmed. 1984 Nov;38(6):913-22. German. No abstract available.

PMID:
6529344
49.

[Function of the endocrine pancreas in cattle. 2. Development of carbohydrate-dependent function and response of the islets to infectious diarrhea].

Hartmann H, Günther H, Lesche R.

Arch Exp Veterinarmed. 1982;36(3):399-416. German. No abstract available.

PMID:
6753787
50.

[The reaction of calves to parenteral administration of cyclopheosphamide].

Steinebach G, Erler W, Heilmann P, Lesche R, Meyer H, Schimmel D, Schönherr W.

Arch Exp Veterinarmed. 1977;31(1):29-51. German.

PMID:
849105

Supplemental Content

Loading ...
Support Center